A New Approach for Cancer Immunotherapy Based on the Cancer Stem Cell Antigens Properties

Author:

Mahmoodi Shirin1,Nezafat Navid2,Negahdaripour Manica2,Ghasemi Younes2

Affiliation:

1. Department of Medical Biotechnology, Fasa University of Medical Sciences, Fasa, Iran

2. Pharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

Abstract

Background: Cancer stem cells (CSCs) are a rare population of tumor cells, which play an important role in tumor initiation, progression, and maintenance. The concept that cancer cells arise from stem cells was presented about 150 years ago. Recently, this hypothesis was renewed considering the heterogeneity of tumor cells. CSCs are resistant to chemo- and radio-therapy. Therefore, targeting CSCs could be a novel and effective strategy to struggle with tumor cells. Objective: In this mini-review, we highlight that different immunotherapeutic approaches can be used to target cancer cells and eradicate different tumor cells. The most important targets are specific markers recognized on the CSC surface as CSC antigens such as CD44, CD133, Aldehyde Dehydrogenase (ALDH), and SOX family members. This article emphasizes recent advances in CSCs in cancer therapy. Results: Our results present that CSC antigens play an important role in tumor initiation, especially in the cells that are resistant to chemo- and radiotherapy agents. Therefore, they are ideal targets for cancer immunotherapy, for instance, in developing different types of cancer vaccines or antibodies against tumor cells. Conclusion: The current studies related to cancer immunotherapy through targeting the CSC antigens based on their properties are briefly summarized. Altogether, CSC antigens can be efficiently targeted to treat cancer patients.

Publisher

Bentham Science Publishers Ltd.

Subject

Molecular Biology,Molecular Medicine,General Medicine,Biochemistry

Reference104 articles.

1. Badve S, Nakshatri H. Breast-cancer stem cells beyond semantics.

2. Akbarzadeh A, Rahmati M, Taheri ZM. Inhibition of hTERT Gene Expression by Silibin in-Loaded PLGA-PEG-Fe 3O4 in T47D Breast Cancer Cell Line Bioimpact

3. Rahmati-Yamchi M, Zarghami N, Rahbani M, Montazeri A. Plasma leptin, hTERT gene expression, and anthropometric measures in obese and non-obese women with breast cancer. Basic and clinical research

4. Neuzil J, Stantic M, Zobalova R. Tumour-initiating cells vs. cancer ‘stem’cells and CD133: what’s in the name?

5. Arens R, van Hall T, van der Burg SH, Ossendorp F, Melief CJ. editors. Prospects of combinatorial synthetic peptide vaccine-based immunotherapy against cancer.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3